Targeting CDK4 in Melanoma
Grant number: 1042986 | Funding period: 2013 - 2015
Major progress has been made in the treatment of cancer by the development of inhibitors of oncogenes that drive cancer growth. This application will test whether this approach can be used for melanomas with activation of the CDK4 oncogene that becomes activated in over 50% of melanomas. We will indentify which patients melanomas respond best to this approach and understand why some melanomas but not other responds providing the scientific framework for clinical trials of CDK4 inhibitors.
Related publications (6)
Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma
Shatha AbuHammad, Carleen Cullinane, Claire Martin, Zoe Bacolas, Teresa Ward, Huiqin Chen, Alison Slater, Kerry Ardley, Laura Kirby, Keefe T Chan, Natalie Brajanovski, Lorey K Smith, Aparna D Rao, Emily J Lelliott, Margarete Kleinschmidt, Ismael A Vergara, Anthony T Papenfuss, Peter Lau, Prerana Ghosh, Sue Haupt
Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are an established treatment in estrogen receptor-positive breast cancer and are c..
Palbociclib synergizes with BRAF and MEK inhibitors in treatment naive melanoma but not after the development of BRAF inhibitor resistance
Claire A Martin, Carleen Cullinane, Laura Kirby, Shatha Abuhammad, Emily J Lelliott, Kelly Waldeck, Richard J Young, Natalie Brajanovski, Donald P Cameron, Rachael Walker, Elaine Sanij, Gretchen Poortinga, Ross D Hannan, Richard B Pearson, Rodney J Hicks, Grant A McArthur, Karen E Sheppard
Increased CDK4 activity occurs in the majority of melanomas and CDK4/6 inhibitors in combination with BRAF and MEK inhibitors are ..
Whole exome sequencing identifies a recurrent RQCD1 P131L mutation in cutaneous melanoma
SQ Wong, A Behren, VJ Mar, K Woods, J Li, C Martin, KE Sheppard, R Wolfe, J Kelly, J Cebon, A Dobrovic, GA McArthur
Melanoma is often caused by mutations due to exposure to ultraviolet radiation. This study reports a recurrent somatic C > T chang..
Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines
Richard J Young, Kelly Waldeck, Claire Martin, Jung H Foo, Donald P Cameron, Laura Kirby, Hongdo Do, Catherine Mitchell, Carleen Cullinane, Wendy Liu, Stephen B Fox, Ken Dutton-Regester, Nicholas K Hayward, Nicholas Jene, Alexander Dobrovic, Richard B Pearson, James G Christensen, Sophia Randolph, Grant A McArthur, Karen E Sheppard
We have investigated the potential for the p16-cyclin D-CDK4/6-retinoblastoma protein pathway to be exploited as a therapeutic tar..